The global Cancer Cell Therapy Market is estimated to be valued at US$ 10799.45 Mn in 2023 and is expected to exhibit a CAGR of 8.9% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Cancer cell therapy utilizes living cells like lymphocytes and stem cells to target and destroy cancer cells. It is an advanced form of immunotherapy that personalizes the treatment according to a patient's immune response and tumor profile. Cancer cell therapy offers certain advantages over conventional therapies like chemotherapy by being more targeted to cancer cells and causing fewer side effects.

Market key trends:
One of the key trends in the cancer cell therapy market is the increasing preference for CAR T-cell therapy. CAR T-cell therapy is an immunotherapy that uses engineered T cells to target specific proteins on cancer cells. Some of the top CAR T-cell therapies approved by FDA in recent years include Kymriah and Yescarta. These therapies have shown encouraging remission rates against blood cancers like acute lymphoblastic leukemia and lymphoma. With ongoing research, CAR T-cell therapies are expected to expand their scope to solid tumors as well going forward.
Market key trends:
One of the key trends in the Global Cancer Cell Market is the growing demand for cell line authentication. Cell lines are an important tool for cancer research. However, several cell lines get contaminated over time, losing their authentic characteristics. This has necessitated the need for cell line authentication to validate cell identity and detect any cross-contamination. Various techniques such as short tandem repeat profiling and mass spectrometry based proteomic analysis are being used by market players for cell line authentication.

SWOT Analysis
Strength: Growing R&D investments from pharmaceutical companies in development of new cell-based cancer therapies.
Weakness: High costs associated with cell line development, maintenance and authentication.
Opportunity: Rising prevalence of cancer worldwide and increasing focus on personalized medicine approaches for treatment.
Threats: Stringent regulatory guidelines for cell-based therapy products and ethical issues related to use of human stem cells.

Key Takeaways
The global cancer cell market is expected to witness high growth, exhibiting CAGR of 8.9% over the forecast period, due to increasing incidence of cancer worldwide.

The North America region is expected to dominate the cancer cell market during the forecast period. This is attributed to growing biotechnology industry, rising R&D activities for cell-based cancer therapies, and presence of major market players in the region.

Europe is also expected to grow at a significant rate during 2023-2030 owing to increasing government funding for cancer research.

Key players operating in the cancer cell market are Abbott Laboratories, Novartis International AG, Arcellx, Autolus Therapeutics, Kite Pharma, Cellectis, Celyad Oncology, Crescendo Biologics Limited, GammaDelta Therapeutics Ltd., Bio-Rad Laboratories Inc, QIAGEN Inc, Thermo Fisher Scientific, Merck Millipore, Siemens Healthineers AG, and GE Healthcare.

Read More: http://igniteblog01.weebly.com/blog/the-development-of-novel-targeted-therapies-is-anticipated-to-openup-the-new-avanue-for-cancer-cell-market